Tachykinin NK1 receptor-mediated vasorelaxation in human pulmonary arteries. 1998

M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
Allergy, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. michel.corboz@spcorp.com

Tachykinin NK1 receptors are present on human pulmonary arteries. Addition of the specific tachykinin NK1 receptor agonist, [Met-OMe11]substance P produced a concentration-dependent relaxation (0.1 nM to 100 nM) in pulmonary arteries preconstricted with phenylephrine (30 microM). The EC50 (agonist concentration needed to produce 50% of the maximal relaxation) value for [Met-OMe11]substance P was 3.7+/-0.7 nM. The relaxation induced by [Met-OMe11]substance P was selectively inhibited by the tachykinin NK1 receptor antagonist CP 99994 (1 nM), with a pKb of 9.9+/-0.3. Treatment with the tachykinin NK2 receptor antagonist SR 48968 (100 nM) did not significantly affect the vasorelaxation due to [Met-OMe11]substance P (P > 0.05, one-way analysis of variance; ANOVA).

UI MeSH Term Description Entries
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D010880 Piperidines A family of hexahydropyridines.
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013373 Substance P An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses. Euler-Gaddum Substance P,Hypothalamic Substance P,SP(1-11),Euler Gaddum Substance P,Substance P, Euler-Gaddum,Substance P, Hypothalamic
D014662 Vasoconstrictor Agents Drugs used to cause constriction of the blood vessels. Vasoactive Agonist,Vasoactive Agonists,Vasoconstrictor,Vasoconstrictor Agent,Vasoconstrictor Drug,Vasopressor Agent,Vasopressor Agents,Vasoconstrictor Drugs,Vasoconstrictors,Agent, Vasoconstrictor,Agent, Vasopressor,Agents, Vasoconstrictor,Agents, Vasopressor,Agonist, Vasoactive,Agonists, Vasoactive,Drug, Vasoconstrictor,Drugs, Vasoconstrictor
D014664 Vasodilation The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE. Vasodilatation,Vasorelaxation,Vascular Endothelium-Dependent Relaxation,Endothelium-Dependent Relaxation, Vascular,Relaxation, Vascular Endothelium-Dependent,Vascular Endothelium Dependent Relaxation
D018040 Receptors, Neurokinin-1 A class of cell surface receptors for TACHYKININS with a preference for SUBSTANCE P. Neurokinin-1 (NK-1) receptors have been cloned and are members of the G protein coupled receptor superfamily. They are found on many cell types including central and peripheral neurons, smooth muscle cells, acinar cells, endothelial cells, fibroblasts, and immune cells. NK-1 Receptors,Neurokinin-1 Receptors,Receptors, Substance P,SP-P Receptors,Substance P Receptors,NK-1 Receptor,Neurokinin-1 Receptor,Receptors, NK-1,Receptors, SP-P,SP-P Receptor,Substance P Receptor,Substance-P Receptor,Tachykinin Receptor 1,NK 1 Receptor,NK 1 Receptors,Neurokinin 1 Receptor,Neurokinin 1 Receptors,P Receptor, Substance,P Receptors, Substance,Receptor, NK-1,Receptor, Neurokinin-1,Receptor, SP-P,Receptor, Substance P,Receptor, Substance-P,Receptors, NK 1,Receptors, Neurokinin 1,Receptors, SP P,SP P Receptor,SP P Receptors

Related Publications

M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
December 2018, Proceedings of the National Academy of Sciences of the United States of America,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
February 2002, European journal of pharmacology,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
January 2004, Pulmonary pharmacology & therapeutics,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
July 1996, Medicinal research reviews,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
April 2001, Trends in pharmacological sciences,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
February 2000, Biochemistry,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
September 2006, Acta anaesthesiologica Scandinavica,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
June 1999, Shock (Augusta, Ga.),
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
October 1997, Trends in pharmacological sciences,
M R Corboz, and M A Rivelli, and S I Ramos, and C A Rizzo, and J A Hey
March 1994, British journal of pharmacology,
Copied contents to your clipboard!